

Susana Otero-Romero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3090351/publications.pdf>

Version: 2024-02-01

31
papers

1,887
citations

471371

17
h-index

377752

34
g-index

34
all docs

34
docs citations

34
times ranked

2430
citing authors

#	ARTICLE	IF	CITATIONS
1	Retinal microvascular abnormalities in patients after COVID-19 depending on disease severity. <i>British Journal of Ophthalmology</i> , 2022, 106, 559-563.	2.1	64
2	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. <i>European Journal of Neurology</i> , 2022, 29, 1075-1081.	1.7	16
3	Impacto de la vacunación de las embarazadas frente a la tosferina en las hospitalizaciones de menores de un año en un hospital de tercer nivel de Cataluña. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022, 40, 473-478.	0.3	2
4	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing/remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2022, 269, 452-459.	1.8	10
5	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 950-957.	1.4	7
6	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. <i>Journal of Neurology</i> , 2022, 269, 1764-1772.	1.8	5
7	Persistent reduction of retinal microvascular vessel density in patients with moderate and severe COVID-19 disease. <i>BMJ Open Ophthalmology</i> , 2022, 7, e000867.	0.8	7
8	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, e1143.	3.1	17
9	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1138-1145.	1.4	11
10	Recomendaciones para la vacunación en pacientes con esclerosis múltiple candidatos a terapias inmunosupresoras: documento de consenso español. <i>Neurología</i> , 2021, 36, 50-60.	0.3	15
11	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021, 28, 3384-3395.	1.7	111
12	Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. <i>Current Opinion in Neurology</i> , 2021, 34, 322-328.	1.8	23
13	Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 285-300.	1.3	12
14	Multiple sclerosis is associated with higher comorbidity and health care resource use: A population-based, case-control study in a western Mediterranean region. <i>European Journal of Neurology</i> , 2021, 28, 4124-4134.	1.7	4
15	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021, 97, e1641-e1652.	1.5	35
16	Optic Nerve Topography in Multiple Sclerosis Diagnosis. <i>Neurology</i> , 2021, 96, e482-e490.	1.5	32
17	Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection. <i>Vaccines</i> , 2021, 9, 1463.	2.1	8
18	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1658-1669.	1.4	41

#	ARTICLE	IF	CITATIONS
19	Italian consensus on treatment of spasticity in multiple sclerosis. <i>European Journal of Neurology</i> , 2020, 27, 445-453.	1.7	20
20	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. <i>Neurology</i> , 2019, 92, e1507-e1516.	1.5	49
21	Multiple sclerosis registries in Europe – An updated mapping survey. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 171-178.	0.9	47
22	ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018, 25, 215-237.	1.7	147
23	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 96-120.	1.4	458
24	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. <i>Multiple Sclerosis Journal</i> , 2018, 24, 721-727.	1.4	6
25	Disability progression markers over 6 years in interferon- β -treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 322-330.	1.4	60
26	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1843-1851.	1.4	77
27	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1386-1396.	1.4	118
28	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , 2016, 87, 1368-1374.	1.5	42
29	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , 2015, 138, 1863-1874.	3.7	403
30	Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe. <i>Journal of the Neurological Sciences</i> , 2015, 359, 146-150.	0.3	8
31	Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. <i>Multiple Sclerosis Journal</i> , 2013, 19, 245-248.	1.4	29